Mass Spec
News on mass spectrometry technology and applications in genetics, genomics, and molecular diagnostics.
C2N Diagnostics Receives $15M From GHR Foundation for Development of Tau Tests for Alzheimer's
The tests will measure blood-based tau markers, offering a possible alternative to PET imaging for aiding in diagnosis and staging of Alzheimer's disease.
New Blood Test Shows 90 Percent Accuracy in Diagnosing Alzheimer’s Disease
Developed by researchers from Lund University in Sweden, the test is more accurate than doctors’ diagnoses using standard clinical evaluation tools.
A retrospective analysis found levels of lipid-based biomarkers such as eicosanoids and sphingolipids were linked with risk of the condition.
Alzheimer's Dx Firms Aim to Take Advantage of Increased Testing Demand Following Leqembi Approval
Premium
Near term, CSF assays and PET imaging will likely remain the methods of choice for evaluating patients for the drug, but blood tests continue to gain traction.
ProPhase Labs Partners With mProbe, Mayo Clinic on Esophageal Cancer Screening Test
The mass spec-based proteomic assay, which was originally developed by Stella Diagnostics, is designed for the early detection of esophageal cancer.